Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly

NCT00765323 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.

NCT NCT00765323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00765323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Open-Label, Multicenter International Study to Evaluate the Efficacy and Safety of an Octreotide Implant vs. Sandostatin LAR Depot in Patients With Acromegaly
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2008
Completion date
June 30, 2011
Enrollment
169 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly